Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 172

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 172
---
 after dilution (million)                            | 1,256.4 |                  | 1,256.9 |                  |
| •Basic earnings per share from continuing operations (€)                     |    4.06 |                  |    6.38 |                  |
| •Basic earnings per share from discontinued operations (€)                   |    0.25 |                  |    0.31 |                  |
| Basic earnings per share (€)                                                 |    4.31 |                  |    6.69 |                  |
| •Diluted earnings per share from continuing operations (€)                   |    4.05 |                  |    6.35 |                  |
| •Diluted earnings per share from discontinued operations (€)                 |    0.25 |                  |    0.31 |                  |
| Diluted earnings per share (€)                                               |    4.30 |                  |    6.66 |                  |

(a) Figures for 2023 and 2022 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.

(1) Non-IFRS financial measure: see definition in “A.2.1 — Presentation of Net Sales.”

| 80 | SANOFIFORM 20-F2024 |

| PART I                                               |
| ITEM 5. Operating and Financial Review and Prospects |

A.3.1. Net sales Consolidated net sales for the year en ded December 31, 2023 a mounted to € 37,817 million, 0.4% higher than in 2022 on a reported basis. Exchange rate fluctuations had a negative effect of 5.0 percentage points overall, due mainly to adverse trends in the US dollar and Argentine peso against the euro. At CER (1) , net sales rose by 5.4% , driven mainly by strong performances for Dupixent and increased sales for our Vaccines business, more than offsetting lower sales for other medicines . Reconciliation of Net sales (IFRS) to net sales at CER (non-IFRS)

| (€ million)(a)                                  |   2023 |   2022 | Change |
| Net sales (IFRS)                                | 37,817 | 37,651 | +0.4%  |
| Effect of exchange rates                        |  1,859 |        |        |
| Net sales at constant exchange rates (non